Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: HIV Infections
Interventions: Dolutegravir + Lamivudine FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 12 more

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Healthy, Hepatic Impairment
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Anaheim, California • Monterey Park, California • Tustin, California + 4 more

Conditions: Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
Interventions: Elemind Neuromodulation Headband, Exercise Routine; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Aerobic Endurance, Metabolism
Interventions: High-amylose maize starch+acetate/butyrate, Low-amylose maize starch; Dietary Supplement · Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 17 Years to 39 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression, Optic Neuritis
Interventions: Reflex (Brightlamp Inc., Purdue University); Diagnostic Test
Lead sponsor: Jagannadha R Avasarala; Other
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Airway Control, Anesthesia, Intubation, Complication
Interventions: Ketamine, Etomidate; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Implantable Cardioverter-Defibrillator With Magnetic Resonance Imaging
Interventions: Patients with a ProMRI ICD System, Magnetic Resonance Imaging (MRI) scan; Device · Other
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more

Conditions: Depressive Disorder, Major
Interventions: Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 18
States / cities: Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: Acid Base Disorder
Interventions: Targeted genomic sequencing; Diagnostic Test
Lead sponsor: Sharp HealthCare; Other
Eligibility: 1 Day to 6 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation; Procedure · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Conditions: Coronary Artery Disease
Interventions: Robotic-assisted PCI; Device
Lead sponsor: Siemens Healthineers Endovascular Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: San Diego, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 14 more

Conditions: Focal Dystonia, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nocturia
Interventions: Desmopressin Melt; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 64
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Acne Scars
Interventions: Multiple Subcision; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Interventions: Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Conjunctivitis, Adenoviral Conjunctivitis
Interventions: RPS Adeno Detector; Device
Lead sponsor: Rapid Pathogen Screening; Industry
Eligibility: 1 Month and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Springfield, Missouri • Philadelphia, Pennsylvania

Conditions: Stage I Endometrial Adenocarcinoma, Uterine Cancer, Obesity
Interventions: Exercise on stationary recumbent exercise cycle, Health Education, Questionnaires, Neuroimaging, Genetic and Biomarkers; Behavioral · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Chronic Genotype 1a or 1b HCV Infection
Interventions: GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule; Drug · Device
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 36
States / cities: Beverly Hills, California • Coronado, California • La Jolla, California + 28 more

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Decatur, Georgia + 5 more

Conditions: Parkinson's Disease
Interventions: Blood Sample Collection, Breath Sample Collection; Other
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Calibration and Validation of Analyte Testing System
Interventions: Minimally invasive and non-invasive blood analyte measurement; Diagnostic Test
Lead sponsor: Kaligia Biosciences, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Timeline: 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Liver Metastases
Interventions: Magnetic Resonance Elastography; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking
Interventions: Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach., Nicotine Replacement Therapy, Varenicline, Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy); Behavioral · Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Combating Alzheimer's Through Sleep and Exercise

Effect of Short-chain Fatty Acids on Aerobic Endurance

Diagnosis of ON With or Without MS or NMOSD

Ketamine Versus Etomidate for Rapid Sequence Intubation

ProMRI Study of the Iforia ICD System (Phase C)

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Rapid Diagnostics for Genetic Disorders in Neonates

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

PRECISION GRX Registry

Depotentiation in People With Focal Hand Dystonia

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Effect of Multiple Subcisions on Rolling Acne Scars

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

Assisted Exercise in Obese Endometrial Cancer Patients

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus

Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes

A Human Clinical Study to Collect Calibration and Performance Data for the RBA-1 and KBS-1

Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases

Metabolism Informed Smoking Treatment: The MIST RCT